Orion Oyj (ORINF)
92.05
0.00 (0.00%)
USD |
OTCM |
Oct 05, 16:00
Orion Max Drawdown (5Y) : 20.69% for Sept. 30, 2026
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| September 30, 2026 | 20.69% |
| August 31, 2026 | 20.69% |
| July 31, 2026 | 20.69% |
| June 30, 2026 | 20.69% |
| May 31, 2026 | 20.69% |
| April 30, 2026 | 20.69% |
| March 31, 2026 | 20.69% |
| February 28, 2026 | 20.69% |
| January 31, 2026 | 20.69% |
| December 31, 2025 | 20.69% |
| November 30, 2025 | 20.69% |
| October 31, 2025 | 20.69% |
| September 30, 2025 | 20.69% |
| August 31, 2025 | 20.69% |
| July 31, 2025 | 20.69% |
| June 30, 2025 | 20.69% |
| May 31, 2025 | 20.69% |
| April 30, 2025 | 20.69% |
| March 31, 2025 | 20.69% |
| February 28, 2025 | 24.40% |
| January 31, 2025 | 24.40% |
| December 31, 2024 | 24.40% |
| November 30, 2024 | 24.40% |
| October 31, 2024 | 24.40% |
| September 30, 2024 | 24.40% |
| Date | Value |
|---|---|
| August 31, 2024 | 24.40% |
| July 31, 2024 | 24.40% |
| June 30, 2024 | 24.40% |
| May 31, 2024 | 24.40% |
| April 30, 2024 | 24.40% |
| March 31, 2024 | 24.40% |
| February 29, 2024 | 24.40% |
| January 31, 2024 | 24.40% |
| December 31, 2023 | 24.40% |
| November 30, 2023 | 24.40% |
| October 31, 2023 | 24.40% |
| September 30, 2023 | 24.40% |
| August 31, 2023 | 24.40% |
| July 31, 2023 | 37.60% |
| June 30, 2023 | 37.60% |
| May 31, 2023 | 37.60% |
| April 30, 2023 | 37.60% |
| March 31, 2023 | 37.60% |
| February 28, 2023 | 37.60% |
| January 31, 2023 | 37.60% |
| December 31, 2022 | 37.60% |
| November 30, 2022 | 37.60% |
| October 31, 2022 | 37.60% |
| September 30, 2022 | 37.60% |
| August 31, 2022 | 37.60% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Max Drawdown (5Y) Benchmarks
| AstraZeneca PLC | 27.87% |
| ANI Pharmaceuticals, Inc. | 72.96% |
| Corcept Therapeutics, Inc. | 71.85% |
| Veru, Inc. | 99.12% |
| Avadel Pharmaceuticals Plc | 90.89% |